Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by chipmuki1234567on Feb 28, 2018 6:44pm

205 Views

Post# 27640115

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Financials are out in SEDAR; no News Release so far

Based on what is stated in the MD&A (I copied it last night), there will be no dilution prior to the release of results in late March. But the company does see favourable conditions to raise equity financing post release of results.

In other words, share price will improve, my guess is around the (0.45 to 0.5) region, and they will raise funds at that point in time.

They most likely will not have a deal right off the bat. Health Canada decision will take place a few months later (deals are typically released at the same time as Health Canada decision but they have outlined 1 year to get a deal with big pharma in the MD&A). Citagenix is sucking cash and Antibe only had about $2M in cash in the end of December 2017. This is one of the reasons you do not see heavy interest in this stock and a much higher market cap as you see with other biotech.

The total share count you see in the financial statements was based on Dec 31, 2017 share price. A lot of warrants were out of money. I have not bothered for a long time, but last I calculated, if all warrants were exercised, 200M (+/- 10%) shares would be outstanding. And if ATB-346 is as big as all the people here say it is, than all warrants will be exercised.

Bullboard Posts

Walmart stock and revenue both on the rise